Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chattem Unlikely To Buy Bristol Brands Due To Excedrin Aversion

This article was originally published in The Tan Sheet

Executive Summary

Chattem would consider buying one of the smaller brands in Bristol-Myers Squibb's consumer medicines unit, excluding Excedrin, President & COO Alec Taylor reported during a Jan. 20 earnings call

You may also be interested in...



Chattem Cites “Dearth Of Good Brands” For Quiet M&A Activity

A string of settled PPA and ephedra cases will allow Chattem to focus more of its bottom line on product development and potential acquisitions

Chattem Cites “Dearth Of Good Brands” For Quiet M&A Activity

A string of settled PPA and ephedra cases will allow Chattem to focus more of its bottom line on product development and potential acquisitions

Chattem Cites “Dearth Of Good Brands” For Quiet M&A Activity

A string of settled PPA and ephedra cases will allow Chattem to focus more of its bottom line on product development and potential acquisitions

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS097757

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel